カテゴリー： DelveInsight, MOA2019, 世界, 医療/バイオ

インターロイキン-12受容体アゴニストのパイプライン・インサイト2019

【英語タイトル】Interleukin-12 (IL-12) Receptor Agonists -Pipeline Insights, 2019

DelveInsightが出版した調査資料（DIMR2016398）・商品コード：DIMR2016398
・発行会社（調査会社）：DelveInsight
・発行日：2019年版（※最新版はお問い合わせください）
・ページ数：約60
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：製薬
◆販売価格オプション（消費税別）
Single User（1名使用）USD1,250 ⇒換算￥131,250見積依頼/購入/質問フォーム
Site Price（同一国内共有可）USD2,500 ⇒換算￥262,500見積依頼/購入/質問フォーム
Enterprise Price（複数国内共有可）USD4,000 ⇒換算￥420,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
本調査レポートでは、世界におけるインターロイキン-12受容体アゴニストのパイプライン動向について調査・分析し、以下の構成でお届けいたします。

・インターロイキン-12受容体アゴニストの概要
・インターロイキン-12受容体アゴニストのパイプライン概要
・企業別開発中のインターロイキン-12受容体アゴニスト
・後期治験段階の薬剤(Filed & Phase III)：比較分析
・中期治験段階の薬剤(Phase II)：比較分析
・初期治験段階の薬剤(Phase I & IND Filed)：比較分析
・薬剤候補のプロファイル
・インターロイキン-12受容体アゴニストの評価
　　- 単剤治療薬別評価
　　- 併用治療薬別評価
　　- 投与経路別評価
　　- 分子種類別評価
・開発が中止された薬剤リスト
・開発休止中の薬剤リスト
・インターロイキン-12受容体アゴニスト開発に取り組んでいる企業リスト
・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “Interleukin-12 (IL-12) Receptor Agonists-Pipeline Insights, 2019”, report provides in depth insights on the pipeline drugs and their development activities around the Interleukin-12 (IL-12) Receptor Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Interleukin-12 (IL-12) Receptor Agonists. DelveInsight’s Report also assesses the Interleukin-12 (IL-12) Receptor Agonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitive pipeline landscape of Interleukin-12 (IL-12) Receptor Agonists
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Interleukin-12 (IL-12) Receptor Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Interleukin-12 (IL-12) Receptor Agonists and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Interleukin-12 (IL-12) Receptor Agonists Overview
• Interleukin-12 (IL-12) Receptor Agonists Disease Associated
• Interleukin-12 (IL-12) Receptor Agonists Pipeline Therapeutics
• Interleukin-12 (IL-12) Receptor Agonists Therapeutics under Development by Companies
• Interleukin-12 (IL-12) Receptor Agonists Filed and Phase III Products
• Comparative Analysis
• Interleukin-12 (IL-12) Receptor Agonists Phase II Products
• Comparative Analysis
• Interleukin-12 (IL-12) Receptor Agonists Phase I and IND Filed Products
• Comparative Analysis
• Interleukin-12 (IL-12) Receptor Agonists Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Interleukin-12 (IL-12) Receptor Agonists – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Interleukin-12 (IL-12) Receptor Agonists – Discontinued Products
• Interleukin-12 (IL-12) Receptor Agonists – Dormant Products
• Companies Involved in Therapeutics Development for Interleukin-12 (IL-12) Receptor Agonists
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Interleukin-12 (IL-12) Receptor Agonists by Therapy Area, 2019
• Number of Products under Development for Interleukin-12 (IL-12) Receptor Agonists, 2019
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2019
• Comparative Analysis Phase II Products, 2019
• Comparative Analysis Phase I and IND Filed Products, 2019
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2019
• Drug Candidates Profiles
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Monotherapy Products
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Combination Products
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Route of Administration
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Stage and Route of Administration
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Molecule Type
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Stage and Molecule Type
• Interleukin-12 (IL-12) Receptor Agonists Therapeutics – Discontinued Products
• Interleukin-12 (IL-12) Receptor Agonists Therapeutics – Dormant Products
• Products under Development by Companies, 2019


List of Figures
• Number of Products under Development for Interleukin-12 (IL-12) Receptor Agonists by Therapy Area, 2019
• Number of Products under Development for Interleukin-12 (IL-12) Receptor Agonists, 2019
• Filed and Phase III Products, 2019
• Phase II Products, 2019
• Phase I and IND Filed Products, 2019
• Discovery and Pre-Clinical Stage Products, 2019
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Monotherapy Products
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Combination Products
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Route of Administration
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Stage and Route of Administration
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Molecule Type
• Interleukin-12 (IL-12) Receptor Agonists Assessment by Stage and Molecule Type


【レポートのキーワード】

インターロイキン-12受容体アゴニスト、医薬品、製薬、研究開発、パイプライン、治療、治験

★調査レポート[インターロイキン-12受容体アゴニストのパイプライン・インサイト2019] (コード：DIMR2016398)販売に関する免責事項を必ずご確認ください。
★調査レポート[インターロイキン-12受容体アゴニストのパイプライン・インサイト2019]についてメールでお問い合わせ

※関連調査レポートはありません。


◆H&Iグローバルリサーチのお客様（例）◆